Medtronic Stock Symbol MDT Complete Stock Report and Analysis

Medtronic is a well-established medical technology company with a rich history dating back to 1949. The company is headquartered in Dublin, Ireland, but is listed on the New York Stock Exchange (NYSE) under the ticker symbol MDT.

Medtronic's stock has a market capitalization of over $140 billion, making it one of the largest medical technology companies in the world. The company's strong financials and innovative products have contributed to its success.

As a leading medical technology company, Medtronic has a diverse portfolio of products and services that cater to various healthcare needs. Its products range from insulin pumps and pacemakers to surgical instruments and spinal implants.

Discover more: Stock Symbol for Berkshire Hathaway B Shares

Medtronic's share price has seen significant fluctuations over the years, with a 52-week high of $93.08 and a low of $75.96. This indicates a considerable price movement.

The company's beta, which measures its volatility relative to the market, is 0.86. This suggests that Medtronic's stock price tends to move in tandem with the broader market.

A different take: Medtronic Dividend Yield

Medtronic's revenue has been steadily increasing, with a 3.64% growth in 2024 compared to the previous year. This is a positive trend for investors.

The company's earnings, however, have seen a slight decline, with a -2.18% decrease in 2024. This may raise some concerns for investors.

Medtronic's analysts have been maintaining a neutral rating, with RBC Capital Markets and Oppenheimer & Co. Inc. both holding a "Hold" rating. This suggests that the analysts are not overly optimistic or pessimistic about the company's prospects.

Here is a summary of the analysts' ratings:

Medtronic's recent Q2 fiscal 2025 results have exceeded street estimates, with revenues and earnings surpassing expectations. This is a positive sign for investors.

Medtronic has a long history of paying dividends, with 47 consecutive years of dividend increases, as seen in the Medtronic Dividend Calendar.

The company has a strong track record of delivering dividend payments, with a current dividend yield of 3.08% and a 3-year dividend growth rate of 6%.

Broaden your view: Stock Symbol B

Medtronic's dividend payout ratio is relatively low at 0.53, indicating that the company is committed to maintaining a healthy dividend policy.

Here's a breakdown of Medtronic's dividend history over the past few years:

The company's dividend payment has been increasing steadily over the years, with a 3-year average annual growth rate of 6%.

Medtronic's dividend yield is also attractive, with a forward dividend yield of 3.09% and a 5-year yield-on-cost of 4.38%.

The company's commitment to dividend payments is reflected in its shareholder yield, which is a whopping 5.87%.

Check this out: Usfr Dividend Yield

Medtronic is making waves in the medical world with a major announcement. The company has received a national coverage analysis from the CMS for their Symplicity Spyral Renal Denervation System.

This is a big deal because it's the first-of-its-kind national coverage analysis for a minimally invasive treatment for high blood pressure. The analysis is supported by a large public health need and robust, long-term data.

Suggestion: Lincoln Financial Stock Symbol

Medtronic has a history of releasing earnings reports and holding annual general meetings. The company's earnings reports have been released on a quarterly basis, with the most recent report being the Q2 2025 Earnings Release on November 19, 2024.

The earnings per share (EPS) for the Q2 2025 Earnings Release was $0.990 USD. This is a significant figure, and it's worth noting that it's the same EPS as the Q3 2024 Earnings Release.

Medtronic's annual general meetings have also been held on a regular basis, with the most recent meeting being held on October 17, 2024. The EPS for this meeting was $2.760 USD.

Here's a list of some of the key events in Medtronic's past:

Medtronic's past earnings reports have provided valuable insights into the company's financial performance.

Kuros Biosciences USA, Inc. has made a significant announcement in the medical industry. They've entered into an exclusive strategic agreement with the Medtronic Spinal Division.

Medtronic will act as the exclusive sales agent for MagnetOsTM in mutually agreed upon sales territories for use in spine surgeries. This partnership aims to expand the reach and availability of MagnetOsTM.

Kuros Biosciences USA, Inc. will work collaboratively with Medtronic to ensure a smooth sales process. This collaboration will help to bring MagnetOsTM to more patients in need.

MagnetOsTM is a product that will be sold through Medtronic's established sales channels. This will provide Kuros Biosciences USA, Inc. with a strong partner to help drive growth.

Curious to learn more? Check out: Ticker Symbol and Stock Exchange for Given Company Neximmune Inc

Renault has appointed Thierry Piéton as its new finance chief.

Thierry Piéton is coming from a role at Medtronic, where he was appointed as Chief Financial Officer.

Medtronic said on Monday it will appoint Renault's finance chief Thierry Piéton as its Chief Financial Officer, effective March 3.

Piéton's new role at Renault will likely bring a fresh perspective to the company's financial management.

Thierry Piéton's appointment at Renault is a significant move for the company, and we can expect to see the impact of his leadership in the coming months.

Related reading: Raspberry Pi Stock Symbol